MIP
Non Small Cell Lung Cancer
Cadila PharnmaceuticalsvaccinePhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 65/ 100
Competitive context
1206 Active assets in the Non Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
d-0316 Betta Pharmaceuticals Co., Ltd. | Phase 2/3 | BBB |
Onartuzumab Hoffmann-La Roche | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
MIP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →